Merck presents phase 3 STRIDE-13 trial results at ESCMID conference in Lisbon

New phase 4 results show sustained symptom relief and improved patient outcomes

Early data reveals strong response rates in ovarian cancer cohort

New partnership aims to fast-track mRNA therapies from lab to clinic

First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex

Novel orexin receptor agonist shows potential to improve wakefulness

Topical TRPV1 antagonist shows promise in heat-induced neuropathic pain

Trial explores regenerative macrophage therapy for liver disease

Deal covers biosimilars for gastroenterology, neurology and dermatology

Collaboration offers end-to-end support from donor sourcing to manufacturing